These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31515083)

  • 1. Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
    Taieb J; Geissler M; Rivera F; Karthaus M; Wilson R; Loupakis F; Price T; Tracy M; Burdon P; Peeters M
    Clin Colorectal Cancer; 2019 Dec; 18(4):245-256.e5. PubMed ID: 31515083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials.
    Peeters M; Price T; Taieb J; Geissler M; Rivera F; Canon JL; Pentheroudakis G; Koukakis R; Burdon P; Siena S
    Br J Cancer; 2018 Aug; 119(3):303-312. PubMed ID: 30013091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials.
    Taieb J; Rivera F; Siena S; Karthaus M; Valladares-Ayerbes M; Gallego J; Geissler M; Koukakis R; Demonty G; Peeters M
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):321-335. PubMed ID: 29080924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).
    Kurreck A; Geissler M; Martens UM; Riera-Knorrenschild J; Greeve J; Florschütz A; Wessendorf S; Ettrich T; Kanzler S; Nörenberg D; Seidensticker M; Held S; Buechner-Steudel P; Atzpodien J; Heinemann V; Stintzing S; Seufferlein T; Tannapfel A; Reinacher-Schick AC; Modest DP
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2681-2691. PubMed ID: 32449003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.
    Manca P; Corallo S; Randon G; Lonardi S; Cremolini C; Rimassa L; Bergamo F; Antoniotti C; Smiroldo V; Zaniboni A; Murialdo R; Tampellini M; Tomasello G; Clavarezza M; Racca P; Antista M; Raimondi A; Prisciandaro M; Pagani F; Palermo F; Greco FG; Vaiani M; Di Bartolomeo M; de Braud F; Calareso G; Morano F; Pietrantonio F
    Eur J Cancer; 2021 Feb; 144():31-40. PubMed ID: 33321462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
    J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
    Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
    Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
    Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer.
    Yoshino T; Uetake H; Tsuchihara K; Shitara K; Yamazaki K; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Yamanaka K; Iwasaki K; Soeda J; Hihara M; Yamanaka T; Ochiai A; Muro K
    Clin Colorectal Cancer; 2017 Jun; 16(2):158-163. PubMed ID: 28237539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
    Raimondi A; Di Maio M; Morano F; Corallo S; Lonardi S; Antoniotti C; Rimassa L; Sartore-Bianchi A; Tampellini M; Ritorto G; Murialdo R; Clavarezza M; Zaniboni A; Adamo V; Tomasello G; Petrelli F; Antonuzzo L; Giordano M; Cinieri S; Longarini R; Bergamo F; Niger M; Antista M; Peverelli G; de Braud F; Di Bartolomeo M; Pietrantonio F
    Eur J Cancer; 2020 Aug; 135():230-239. PubMed ID: 32623288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer.
    Douillard JY; Siena S; Peeters M; Koukakis R; Terwey JH; Tabernero J
    Eur J Cancer; 2015 Jul; 51(10):1231-42. PubMed ID: 25956209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
    Cheng AL; Cornelio G; Shen L; Price T; Yang TS; Chung IJ; Dai GH; Lin JK; Sharma A; Yeh KH; Ma B; Zaatar A; Guan Z; Masood N; Srimuninnimit V; Yau T; Gibbs P; Wang X; Doval DC; Oh ST; Shim BY; Gorospe C; Wang HM; Sirachainan E; Hill A; Suh KW; Beier F; Chatterjee S; Lim R
    Clin Colorectal Cancer; 2017 Jun; 16(2):e73-e88. PubMed ID: 27780749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
    Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
    Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFOXIRI Plus Panitumumab As First-Line Treatment of
    Modest DP; Martens UM; Riera-Knorrenschild J; Greeve J; Florschütz A; Wessendorf S; Ettrich T; Kanzler S; Nörenberg D; Ricke J; Seidensticker M; Held S; Buechner-Steudel P; Atzpodien J; Heinemann V; Seufferlein T; Tannapfel A; Reinacher-Schick AC; Geissler M
    J Clin Oncol; 2019 Dec; 37(35):3401-3411. PubMed ID: 31609637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
    Modest DP; Rivera F; Bachet JB; de Braud F; Pietrantonio F; Koukakis R; Demonty G; Douillard JY
    Int J Cancer; 2019 Jul; 145(2):576-585. PubMed ID: 30614531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
    Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.
    Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
    Clin Colorectal Cancer; 2018 Sep; 17(3):170-178.e3. PubMed ID: 29627309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.